ProPhase Labs PRPH

ProPhase Labs, Inc. is a growth-oriented and diversified biotechnology, genomics, and consumer products company engaged in developing and commercializing novel drugs, dietary supplements, and genomic testing services.

Revenue is generated through the sale of whole genome sequencing solutions, dietary supplement products, and diagnostic laboratory services. Core offerings include consumer genomics testing via digital platforms and strategic partnerships, branded nutritional products marketed for health and vitality, and specialized clinical assays supported by proprietary intellectual property.

The company operates through the following segments: ProPhase BioPharma, Nebula Genomics, DNA Complete, ProPhase Diagnostics, and TK Supplements.

• ProPhase BioPharma: This segment focuses on the licensing, development, and commercialization of novel drugs, dietary supplements, and compounds. It holds exclusive worldwide rights to develop and commercialize LB-1 and LB-2, modified polyphenol compounds derived from Myricetin, for potential use in treating cancer, inflammatory diseases, and neurodegenerative conditions including Alzheimer’s disease. The segment also manages the Equivir licensing agreement with Global BioLife, which grants rights to exploit immune-supportive compounds for commercialization.
• Nebula Genomics: Nebula provides consumers access to affordable and secure whole genome sequencing, decoding approximately 6.4 billion base pairs of the human genome to generate detailed genetic reports. Customers receive over 300 personalized reports covering traits related to longevity, mental health, cancer risk, and drug response, accessible via a secure online portal. The platform includes exploratory tools such as a gene browser and gene analysis tool, along with weekly educational content and a subscription model delivering updated reports as new scientific insights emerge.
• DNA Complete: DNA Complete specializes in genomics testing technologies, offering three tiers of whole genome sequencing—Essential, Pro, and Elite—corresponding to 1x, 30x, and 100x coverage, respectively, with escalating numbers of personalized health reports exceeding 175, 250, and 350 per tier. The service includes ancestry and health insights spanning disease predispositions, metabolic traits, and longevity factors. Additionally, DNA Complete offers DNA Expand, a platform enabling users to upload raw DNA data from other providers to uncover up to 50x more data points from over 35 million genetic variants for enhanced wellness reporting.
• TK Supplements: The TK Supplements® product line is dedicated to supporting better health, energy, and sexual vitality through scientifically formulated herbal blends. Key branded products include Legendz XL®, marketed as a male sexual enhancement supplement, and Triple Edge XL®, positioned as an energy and stamina booster. The company anticipates launching Equivir, a daily immune-support supplement, pending final trial results from studies conducted in India with Vedic Lifesciences.

ProPhase Labs operates in highly competitive markets dominated by large entrenched players, particularly in clinical diagnostics where it faces competition from national laboratory giants such as Quest Diagnostics and LabCorp, as well as integrated health systems. In the direct-to-consumer genomics space, the company contends with established brands offering similar sequencing and reporting services, though it differentiates through pricing innovation, report depth, and subscription-based updates. Its dietary supplement business competes on product quality, formulation science, and brand recognition within a crowded OTC marketplace where consumer trust and regulatory compliance are critical differentiators.

The company serves individual consumers purchasing genetic testing kits and dietary supplements online or through planned retail distribution in food, drug, and mass merchants. It also supports academic institutions conducting genomic research and collaborates with medical institutions such as the Mayo Clinic, Dana-Farber Cancer Institute, and Harvard Medical School on therapeutic and diagnostic development initiatives. Additionally, prior to its deconsolidation, ProPhase Diagnostics served patients and healthcare providers through its CLIA-certified laboratories in New Jersey and New York, offering PCR and antigen testing for respiratory pathogens including SARS-CoV-2 and influenza.